Idorsia Ltd (0RQE.L)

12,25 -0,29 (-2,28%) Alla chiusura: 06:10PM BST

Idorsia Ltd

Hegenheimermattweg 91
Allschwil 4123
Switzerland
41 58 844 10 10
https://www.idorsia.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jean-Paul Clozel M.D.	CEO & Executive Director	1,38M	N/D	1955
Mr. André C. Muller	Executive VP & CFO	N/D	N/D	1963
Dr. Martine Clozel	Executive VP & Chief Scientific Officer	N/D	N/D	1955
Mr. Andrew C. Weiss	Senior VP and Head of Investor Relations & Corporate Communications	N/D	N/D	1968
Mr. Julien Gander L.L.M.	Senior VP, Group General Counsel & Company Secretary	N/D	N/D	1979
Mr. Alexander Khatuntsev	Senior VP & Head of Global Human Resources	N/D	N/D	1978
Dr. Guy Braunstein M.D.	Executive VP & Chief Medical Officer	N/D	N/D	1956
Mr. Olivier Lambert	Senior VP & Head of Technical Operations	N/D	N/D	1966
Mr. Markus A. Riederer	Senior VP & Head of Drug Discovery Biology	N/D	N/D	1962
Mr. Christoph Boss	Senior VP & Head of Drug Discovery Chemistry	N/D	N/D	1968

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di Idorsia Ltd al 1 aprile 2024 è 2. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.